Crossmark

Investigation of Aframomum melegueta compounds as ERK5 inhibitor related to breast cancer via molecular docking and dynamic simulation

Published Online: 2025-01-25

Authors

Ottu, Paul Olamide

Babalola, Olorunfemi Oyewole

Oluwamodupe, Cecilia

Oluwatobiloba, Ayodeji Folasade

Kehinde, Idayat Oyinkansola

Akinola, Olufemi Adebisi

Ibrahim, Sulyman Olalekan

Elekofehinti, Olusola Olalekan
License Information

Text and Data Mining valid from 2025-01-25

Version of Record valid from 2025-01-25
More Information

Article History

Received: 13 November 2024

Accepted: 12 January 2025

First Online: 25 January 2025

Declarations

:

: The authors declare no competing interests.

Document is current